Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma
Adolfo Aleman(Icahn School of Medicine at Mount Sinai), Maria C. Bermúdez‐González(Icahn School of Medicine at Mount Sinai), A. Azad, L.C.F. Mulder, Kevin Tuballes(Icahn School of Medicine at Mount Sinai), Sundar Jagannath(Mount Sinai Hospital), Daniel Floda(Icahn School of Medicine at Mount Sinai), Sarita Agte(Northwestern University), Kayla T. Russo(Icahn School of Medicine at Mount Sinai), Miti Saksena(Icahn School of Medicine at Mount Sinai), Ania Wajnberg(Icahn School of Medicine at Mount Sinai), Katherine F. Beach(Icahn School of Medicine at Mount Sinai), Gianna Y. Cai(Icahn School of Medicine at Mount Sinai), Charles Gleason(Icahn School of Medicine at Mount Sinai), Komal Srivastava(Icahn School of Medicine at Mount Sinai), Giulio Kleiner(Icahn School of Medicine at Mount Sinai), Wanni A. Mendez(Icahn School of Medicine at Mount Sinai), Brian D. Brown(Tisch Hospital), Levy A. Sominsky(Icahn School of Medicine at Mount Sinai), A. Oostenink, Neko Lyttle(Icahn School of Medicine at Mount Sinai), Sacha Gnjatic(Mount Sinai Hospital), Dalles Andre(Icahn School of Medicine at Mount Sinai), Carlos Cordon‐Cardo(Icahn School of Medicine at Mount Sinai), Miriam Merad(Icahn School of Medicine at Mount Sinai), Katerina Kappes(Icahn School of Medicine at Mount Sinai), Bhaskar Upadhyaya(Icahn School of Medicine at Mount Sinai), Karen David, Amber A. Shin, Christian Cognigni(Icahn School of Medicine at Mount Sinai), Radhika Banu(Icahn School of Medicine at Mount Sinai)
Cited by 76
Related Papers
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Intraepithelial CD8 <sup>+</sup> tumor-infiltrating lymphocytes and a high CD8 <sup>+</sup> /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
|Proceedings of the National Academy of Sciences|2005|2.4k
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k